Clinical Trials Logo

Clinical Trial Summary

Cutaneous leishmaniasis manifestations range from self-healing localized skin ulcers/nodules to diffusely spread chronic lesions. Knowledge on the host-parasite interactions underpinning the different clinical presentations is scarce, in particular for L. aethiopica infections where disease can be extremely severe. Our aim is to define differences in skin immune responses and parasite virulence in CL patients at single cell/parasite level and how it underpins the different clinical presentations (localised, mucocutaneous and diffuse), by producing the first spatially-resolved 'ecological' map of the lesions.


Clinical Trial Description

Specific objectives: 1. To profile the full heterogeneity in skin and lesion immunity (single cell RNAseq), and the cellular microenvironment surrounding infected and non-infected macrophages (digital spatial profiling). 2. To study the genomic diversity of L. aethiopica and identify features associated with the different clinical presentations (whole genome sequencing). 3. To understand how parasites respond to the microenvironmental conditions and define parasite survival niches (digital spatial profiling). 4. Study metabolic determinants of skin immunity (e.g. lipid metabolism, bioenergetics, short-chain fatty acids) in the context of key structural features of the skin landscape known to influence local metabolism and immune response (e.g. adipose tissue, follicles, microvasculature) (SpatialOMx). 5. To investigate the association between patient outcomes and the above host/parasite factors at baseline. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05332093
Study type Observational [Patient Registry]
Source Institute of Tropical Medicine, Belgium
Contact Thao-Thy Pham, PhD
Phone +32474642614
Email thaothypham@itg.be
Status Recruiting
Phase
Start date March 21, 2022
Completion date December 30, 2023

See also
  Status Clinical Trial Phase
Suspended NCT03292835 - Complex Cutaneous Leishmaniasis Healing Study in Algeria
Terminated NCT03208543 - Effectiveness, Safety and Feasibility of HECT-CL, in Quetta, Pakistan Phase 3
Completed NCT04512742 - A Clinical Study to Develop a Controlled Human Infection Model Using Leishmania Major-infected Sand Flies N/A
Completed NCT04004754 - Outcomes of Complicated CL in Ethiopia Treated With Miltefosine
Active, not recruiting NCT04515186 - Combination, Miltefosine Monotherapy for Cutaneous Leishmaniasis in New World Phase 3
Completed NCT02919605 - Efficacy and Safety of Pentamidine (7mg/kg) for Patients With Cutaneous Leishmaniasis Caused by L. Guyanensis Phase 2
Completed NCT03837431 - Cutaneous Leishmaniasis Diagnostic Study
Not yet recruiting NCT05493059 - Study of Cases of Cutaneous Leishmaniasis Treated With Miltefosine in French Guiana, Retrospective Study
Terminated NCT04001335 - Diagnosis of Cutaneous Leishmaniasis Using the CL-detect Rapid Test in Travelers and Migrants in Belgium
Completed NCT03929016 - Single Oral Dose Escalation Study of DNDI-0690 in Healthy Subjects Phase 1
Completed NCT03435419 - Evaluation of Point-of-care Tests for the Diagnosis of Cutaneous Leishmaniasis in Afghanistan N/A